IDBS Advances Drug Development with Polar Platform Innovations and AI Investments in 2025
核心洞察
IDBS (搜索), a Danaher (搜索) company, launched Polar Control, a "drug development recipe book" capability within its GxP-compliant Polar platform, targeting inefficiencies in process lifecycle management and tech transfer.
The company introduced a cloud-native integration framework and expanded its Polar accelerator library with workflow and insight apps spanning bioanalysis, DMPK, stability, and bioprocess oversight.
IDBS (搜索) advanced its AI capabilities, including Agentic AI proof-of-concept work to accelerate the "Lab Loop," and reported roughly 10% engineering productivity gains from AI integration into its software development lifecycle.
IDBS (搜索), a Danaher (搜索) company, has advanced its Polar enterprise lab informatics platform throughout 2025 with a series of product launches, AI investments, and customer milestones aimed at accelerating the drug development lifecycle. The company started the year with the launch of Polar Control, a new "drug development recipe book" capability within IDBS Polar, a GxP-compliant platform offering ELN, LES and LIMS capabilities. Polar Control is a purpose-built solution for parameter and process lifecycle management, directly addressing critical inefficiencies in developing process knowledge and managing tech transfer.
Enhancing Process Lifecycle Management and Tech Transfer
The Polar Control launch targets a persistent challenge in pharmaceutical development: the efficient management of process parameters and the transfer of technology across development stages. By providing a dedicated capability for parameter and process lifecycle management, IDBS (搜索) aims to streamline how organizations build process knowledge and execute tech transfer, reducing the friction that often slows the transition from discovery to development.
Turning Data into Actionable Insights Through Integration
IDBS (搜索) introduced a cloud-native integration framework for its Polar platform, enabling automated transfer of large data sets, broader data-type support and simplified configuration. The first use case, showcased at the i3 user group meeting, featured a connector for Cytiva (搜索)'s UNICORN software, delivering seamless workflows for downstream purification and turning chromatography data into actionable insights.
Redefining Scientific Workflows with Accelerators
IDBS (搜索) expanded its Polar accelerator library with workflow and insight apps designed to streamline operations, enhance compliance and deliver faster, high-quality data. Among the new capabilities:
- The BioA Study Report Insight App provides real-time visibility into bioanalysis operations, helping study directors spot bottlenecks, accelerate decisions and maintain full 21 CFR Part 11 compliance.
- The DMPK in vivo and in vitro Workflows & Insight App automates calculations, standardizes processes and enables cross-study comparisons, delivering faster, reproducible pharmacokinetic data.
- The Stability Workflow & Insight App simplifies stability study design and execution with real-time progress tracking, sample scheduling and test result visibility.
- The Analytical Method Development Workflow & Insight App simplifies clinical-phase method development with structured data capture, protocol-driven assay configuration and GxP-compliant workflows.
- An OPC Data Import modular workflow, used with the Preparative Chromatography accelerator, automates UNICORN software data import into the IDBS Advance workflow.
- The BioP Study Report Insight App consolidates bioprocess data from cell line development to analytical development.
- The EVE Accelerator Template empowers workflow builders to develop custom workflows faster with pre-configured starting points and standardized configurations.
- The Project Tracking Insight App provides centralized visibility into project milestones, timelines and deliverables.
AI Investments to Accelerate Innovation
In 2025, IDBS (搜索) advanced its AI capabilities to support scientists in everyday tasks such as summarizing scientific papers, identifying key experimental findings, and enabling natural-language semantic search. The company is also investing in Agentic AI to accelerate the "Lab Loop." By leveraging governed, contextualized data within the IDBS Polar data backbone, scientists will be able to learn from prior experiments to automatically design and refine workflows, speeding results and potentially transforming the drug development lifecycle. This work is currently in proof-of-concept.
Additionally, IDBS (搜索) integrated AI into its Software Development Lifecycle (SDLC) in collaboration with Danaher (搜索)'s Enterprise AI team. Early adoption has improved engineering productivity by about 10%.
Celebrating Customer Successes
IDBS (搜索) celebrated customer achievements in 2025, including BioIVT (搜索)'s 30% reduction in study cycle times using IDBS software. At the annual IDBS i3 2026 Forum, customers and partners demonstrated transformative applications of IDBS Polar and the value of the GxP compliance framework. Looking ahead, IDBS will continue to spotlight innovation at i3 2026 in Boston on May 18.
Commitment to Quality and Sustainability
In 2025, IDBS (搜索) achieved ISO/IEC 27017 certification, an internationally recognized standard for cloud security controls, complementing the company's existing ISO 27001 certification. This milestone underscores the company's commitment to safeguarding customer data and maintaining the highest standards of information security. IDBS also earned a Bronze Medal from EcoVadis, a global leader in sustainability assessment.
Industry Recognition
IDBS (搜索) was honored with the Best Bioprocessing Supplier Award: Software at the Asia Pacific Biopharma Excellence Awards 2025, recognizing its leadership in delivering innovative, high-quality solutions for bioprocessing. Independent market research ranked IDBS top for GxP compliance support and expertise among eight leading vendors in R&D, preclinical CROs, and process development. In a separate study comparing ten scientific lab data platforms, IDBS achieved the highest satisfaction and was recognized as the most widely used platform.